Universal Pharmacare in Canada: A Prescription for Equity in Healthcare

Document Type: Editorial

Authors

1 School of Health Administration, Dalhousie University, Halifax, NS, Canada

2 Schulich School of Law, Dalhousie University, Halifax, NS, Canada

Abstract

Despite progressive universal drug coverage and pharmaceutical policies found in other countries, Canada remains the only developed nation with a publicly funded healthcare system that does not include universal coverage for prescription drugs. In the absence of a national pharmacare plan, a province may choose to cover a specific sub-population for certain drugs. Although different provinces have individually attempted to extend coverage to certain subpopulations within their jurisdictions, out-of-pocket expenses on drugs and pharmaceutical products (OPEDP) accounts for a large proportion of out-of-pocket health expenses (OPHE) that are catastrophic in nature. Pharmaceutical drug coverage is a major source of public scrutiny among politicians and policy-makers in Canada. In this editorial, we focus on social inequalities in the burden of OPEDP in Canada. Prescription drugs are inconsistently covered under patchworks of public insurance coverage, and this inconsistency represents a major source of inequity of healthcare financing. Residents of certain provinces, rural households and Canadians from poorer households are more likely to be affected by this inequity and suffer disproportionately higher proportions of catastrophic out-of-pocket expenses on drugs and pharmaceutical products (COPEDP). Universal pharmacare would reduce COPEDP and promote a more equitable healthcare system in Canada.

Highlights

Commentaries Published on this Paper and Lewis Paper

 

  •  National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability; Comment on “Universal Pharmacare in Canada: A Prescription for Equity in Healthcare”

            Abstract | PDF

 

  •  It’s Time to Finally Kill the Zombies; Comment on “Universal Pharmacare in Canada”

             Abstract | PDF

Keywords

Main Subjects


  1. Wirtz VJ, Hogerzeil HV, Gray AL, De Joncheere C, Ewen M. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403-476. doi:10.1016/S0140-6736(16)31599-9
  2. Morgan SG, Martin D, Gagnon M-A, Mintzes B, Daw JR, Lexchin J. Pharmacare 2020: The Future of Drug Coverage in Canada. Vancouver: Pharmaceutical Policy Research Collaboration, University of British Columbia; 2015.
  3. World Health Organization. Health Systems Financing: The Path to Universal Coverage. Geneva, Switzerland: WHO; 2010.
  4. World Health Organization. The World Health Report 2000 - Health Systems: Improving Performance. Geneva, Switzerland: WHO; 2000.
  5. World Health Organization. Making fair choices on the path to universal health coverage.  Bull World Health Organ 2014;92:389. doi:10.2471/blt.14.139139
  6. World Health Organization. Equitable access to essential medicines: a framework for collective action. Geneva, Switzerland: WHO; 2004.
  7. Culyer AJ, Wagstaff A. Equity and equality in health and health care. J Health Econ. 1993;12:431-457. doi:10.1016/0167-6296(93)90004-X
  8. Wagstaff A, van Doorslaer E, Calonge S, et al. Equity in the finance of health care: some international comparisons. J Health Econ. 1992;11:361-387. doi:10.1016/0167-6296(92)90012-P
  9. Martin D, Miller AP, Quesnel-Vallée A, Caron NR, Vissandjée B, Marchildon GP. Canada’s universal health-care system: achieving its potential. Lancet. 2018;391:1718-1735. doi:10.1016/S0140-6736(18)30181-8
  10. Advisory Council on the implementation of National Pharmacare. A Prescription for Canada: Achieving Pharmacare for All - Final Report of the Advisory Council on the Implementation of National Pharmacare. Ottawa, Ontario; 2019.
  11. Caldbick S, Wu X, Lynch T, Al-Khatib N, Andkhoie M, Farag M. The financial burden of out of pocket prescription drug expenses in Canada. Int J Heal Econ Manag. 2015;15(3):329-338. doi:10.1007/s10754-015-9171-3
  12. Marchildon GP, Jackson A. Charting the Path to National Pharmacare in Canada. Ottawa: Broadbent Institute; 2019.
  13. Hall EM. Royal Commission on Health Services. Ottawa: Queen's Printer; 1964.
  14. Romanow R. Building on Values: The Future of Health Care in Canada. Commission on the Future of Health Care in Canada; 2002.
  15. Government of Canada. Towards Implementation of National Pharmacare. Government of Canada; 2018.
  16. McLeod L, Bereza BG, Shim M, Grootendorst P. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data. Open Med. 2011;5(1):e1-9.
  17. Edmonds S, Hajizadeh M. Assessing progressivity and catastrophic effect of out-of-pocket payments for healthcare in Canada: 2010–2015. Eur J Heal Econ. 2019;20(7):1001-1011. doi:10.1007/s10198-019-01074-x
  18. Brandt J, Shearer B, Morgan SG. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare. J Pharm Policy Pract. 2018. doi:10.1186/s40545-018-0154-x
  19. Morgan SG, Boothe K. Universal prescription drug coverage in Canada: Long-promised yet undelivered. Healthc Manag Forum. 2016;29(6):247-254. doi:10.1177/0840470416658907
  20. Morgan SG, Law M, Daw JR, Abraham L, Martin D. Estimated cost of universal public coverage of prescription drugs in Canada. CMAJ. 2015;187(7):491-497. doi:10.1503/cmaj.141564
  21. Morgan SG, Li W, Yau B, Persaud N. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada. CMAJ. 2017;189(8): E295-E302. doi:10.1503/cmaj.161082
  22. Wolfson MC, Morgan SG. How to pay for national pharmacare. CMAJ. 2018;190(47):E1384-E1388. doi:10.1503/cmaj.180897
  23. Law MR, Cheng L, Dhalla IA, Heard D, Morgan SG. The effect of cost on adherence to prescription medications in Canada. CMAJ. 2012;184(3):297-302. doi:10.1503/cmaj.111270
  24. Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: A cross-sectional analysis of a survey in 11 developed countries. BMJ Open. 2017;7:e014287. doi:10.1136/bmjopen-2016-014287
  25. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJL. Household catastrophic health expenditure: A multicountry analysis. Lancet. 2003;362(9378):111-117. doi:10.1016/S0140-6736(03)13861-5
  26. OECD. Growing Unequal?: Income Distribution and Poverty in OECD Countries. Paris, France: OECD Publishing; 2008. doi:10.1787/9789264044197-en
  27. OECD. Special Focus: Inequality in Emerging Economies (EE’s). In: Divid We Stand: Why Inequal Keeps Rising. OECD; 2011:47-82. doi:10.1787/9789264119536-en
  28. O’Donnell O, van Doorslaer E, Wagstaff A, Lindelow M. Analyzing Health Equity Using Household Survey Data - A Guide to Techniques and Their Implementation. Geneva: The World Bank; 2008.
  29. Amaya-Lara JL. Catastrophic expenditure due to out-of-pocket health payments and its determinants in Colombian households. Int J Equity Health. 2016;15(1):1-11. doi:10.1186/s12939-016-0472-z
  30. Mataria A, Raad F, Abu-Zaineh M, Donaldson C. Catastrophic Healthcare Payments and Impoverishment in the Occupied Palestinian Territory. Appl Health Econ Health Policy. 2010;8(6):393-405. doi:10.2165/11318200-000000000-00000
  31. Tomini SM, Packard TG, Tomini F. Catastrophic and impoverishing effects of out-of-pocket payments for health care in Albania: Evidence from Albania Living Standards Measurement Surveys 2002, 2005 and 2008. Health Policy Plan. 2013;28(4):419-428. doi:10.1093/heapol/czs073
  32. Wagstaff A, Doorslaer E van. Catastrophe and impoverishment in paying for health care: with applications to Vietnam 1993-1998. Health Econ. 2003;12(11):921-933. doi:10.1002/hec.776
  33. Hennessy D, Sanmartin C, Ronksley P, et al. Out-of-pocket spending on drugs and pharmaceutical products and costrelated prescription non-adherence among Canadians with chronic disease. Health Rep. 2016;27(6):3-8.
  34. Statistics Canada. User Guide for the Survey of Household Spending, 2016. The Statistics Canada; 2017. https://www150.statcan.gc.ca/n1/pub/62f0026m/62f0026m2018001-eng.pdf.